HIV / AIDS
Risk of Strokes Is Increasing for People with HIV
- Details
- Category: Cardiovascular Disease
- Published on Friday, 28 January 2011 12:55
The number of HIV positive people hospitalized due to ischemic strokes -- the type caused by blocked blood flow to the brain -- increased by 60% over the past decade, even as the number fell among the U.S. population at large, according to research described in the January 19, 2011, advance online issue of Neurology. Even after accounting for the larger number of people living with HIV, stroke risk increased by about 40% since 2001.
Expanded HIV Screening and Treatment Could Prevent More than 200,000 New Infections
- Details
- Category: HIV Testing & Diagnosis
- Published on Friday, 28 January 2011 12:55
One-time HIV screening of the entire adult population plus annual screening of people at higher risk could prevent nearly 7% of projected new infections, while treating more eligible people with antiretroviral therapy (ART) could raise the proportion of averted infections to about 17%, according to research described in the December 21, 2010, Annals of Internal Medicine. Investigators estimated that the cost of the combined strategy would be about $21,500 per year of life saved.
New Report Outlines Persistent Health Disparities in U.S.
- Details
- Category: HIV Treatment
- Published on Tuesday, 25 January 2011 12:55
Health disparities based on race/ethnicity and socioeconomic status remain a persistent problem in the U.S. despite efforts to combat them, according to a new report from the Centers for Disease Control and Prevention (CDC) published in the January 14, 2011, Morbidity and Mortality Weekly Report supplement. Infant mortality remains higher among African-Americans, poor people spend more days sick than those with higher incomes, and disparities in HIV infection rates are widening, with blacks and gay/bisexual men bearing the greatest burden.
Research Reveals Complete Structure of HIV's Capsid Shell
- Details
- Category: HIV Basic Science
- Published on Friday, 28 January 2011 07:18
Up to 30% of People with HIV Develop Neutralizing Antibodies that May Slow Disease Progression
- Details
- Category: HIV Basic Science
- Published on Tuesday, 25 January 2011 12:55
Between 10% and 30% of people with HIV produce broadly cross-reactive antibodies against the virus during the first few years of infection, according to research published in the January 13, 2011, edition PLoS Pathogens. These early antibodies, which target a conserved region of HIV's outer envelope, are associated with lower plasma viral load, and investigators suggested their findings could aid development of an effective vaccine.
Gender, Race, and Geographic Disparities in HIV/AIDS Outcomes
- Details
- Category: HIV Treatment
- Published on Tuesday, 25 January 2011 23:20
Women, blacks, and people living in the southern U.S. had poorer HIV treatment outcomes than other groups, according to a study of more than 2000 seroconverters described in the February 15, 2011 Journal of Infectious Diseases. People from these disadvantaged populations were less likely to start antiretroviral therapy (ART) and more likely to experience HIV/AIDS-related events over 8 years of follow-up; those who started treatment, however, responded equally well after the first 6 months.
Prevention Task Force Recommends Wider Bone Screening for Older Women
- Details
- Category: Bone Loss/Osteoporosis
- Published on Friday, 21 January 2011 23:50
The U.S. Preventive Services Task Force (USPSTF) this week issued revised guidelines, published in the January 17, 2011, advance online edition of Annals of Internal Medicine, recommending that all women age 65 and older should be screened for bone loss, along with younger women -- and presumably men -- who have equivalent risk. HIV and its treatment may raise the likelihood of bone loss, and experts recently recommended earlier bone screening for HIV positive women and men.
More Articles...
- Discordant Responders Do Well If Viral Load Remains Suppressed
- HIV Positive Teens May Need Modified Atazanavir Dose
- Cell Marker Linked to Poor Immune Recovery on Antiretroviral Therapy
- Gilead Will Extend Phase 3 Elvitegravir Trial to 96 Weeks
- Can Genetic Testing Predict Antiretroviral Drug Side Effects?
Web Design and Development by